Enzalutamide resistance in prostate cancer

LNCaP (clone FDG) and C42B cells were purchased from ATCC and were grown in RPMI 1640 media (GIBCO # 11875093) supplemented with 10% Fetal Bovine Serum (FBS, Corning Cat#35-011-CV) and maintained at 37 °C and 5% CO₂. Enzalutamide powder was purchased from Sellekchem (cat #S1250) and re-suspended in DMSO. Cells were plated in 6-well plates and treated either with DMSO, or with Enzalutamide (20 μM), refreshed every 4 days for up to 3 months until the resistance emerged. RNA from cells was extracted on indicated days using the methods described below.

Free full text: Click here

Panja S., Truica M.I., Yu C.Y., Saggurthi V., Craige M.W., Whitehead K., Tuiche M.V., Al-Saadi A., Vyas R., Ganesan S., Gohel S., Coffman F., Parrott J.S., Quan S., Jha S., Kim I., Schaeffer E., Kothari V., Abdulkadir S.A, & Mitrofanova A. (2024). Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nature Communications, 15, 352.

Publication 2024

RPMI 1640 media FBS Enzalutamide

Corresponding Organization :

Other organizations : Rutgers, The State University of New Jersey, Northwestern University

Top 5 similar protocols

Variable analysis

independent variables

Treatment with DMSO (control)
Treatment with Enzalutamide (20 μM)

dependent variables

Emergence of resistance

control variables

Cell lines: LNCaP (clone FDG) and C42B cells
Culture media: RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS)
Incubation conditions: 37 °C and 5% CO2
Duration of treatment: up to 3 months until resistance emerged

negative control

DMSO

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!